



PRESS RELEASE JANUARY 17th 2012

MOBERG DERMA STRENGTHENS MANAGEMENT TEAM

Moberg Derma AB (STO: MOB) has hired Lena Pereswetoff-Morath as Vice President Pharmaceutical Innovation & Development. Lena comes from a similar position at Orexo and has extensive experience in drug development, e.g. from Biolipox and AstraZeneca.

"We have seen strong sales growth for NaloxTM and the additional contracts and product launches create opportunities for international expansion and continued growth. Lena brings valuable experience to the organization in the expansion phase. I am happy to welcome Lena to the team", says Peter Wolpert, President and CEO of Moberg Derma.

For further information, please contact:

Peter Wolpert, President and CEO

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR

Mobile: +46 73-355 26 01

E-mail: magnus.persson@mobergderma.se

About Moberg Derma

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma's first product NaloxTM/Emtrix[®] - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se